POLARIS Study FAQs
Frequently Asked Questions
Will I still need insulin?
All participants continue standard diabetes care in concordance with your physician
Will I continue my standard diabetes care if I join?
Yes. Participation in this study does not replace ongoing medical care or prescribed therapies such as insulin
Has GNTI-122 been given to humans before?
No, this is a first-in-human clinical study.
How long does the study last?
Participants are followed for up to 78-weeks after treatment.
Is participation safe?
All clinical trials involve risk. Safety is closely monitored, and potential risks are reviewed before enrollment.
Can I leave the study?
Participation is voluntary, and participants may withdraw at any time.
Will I be compensated for participation in this study?
You will be compensated for travel to and from the study site, as well as for every visit that is completed.
How is my blood glucose monitored?
Continuous glucose monitor (Dexcom G7) will be supplied for the study. but not for the entire duration of the study.
Is GNTI-122 approved by the FDA?
GNTI-122 is an investigational therapy that has been approved by the FDA for a clinical trial.
Has the study been approved for use in humans?
The POLARIS Study protocol has been reviewed and approved by independent ethics committees, commonly known as Institutional Review Boards (IRBs). These committees include medical professionals and community members who help ensure that clinical research is conducted ethically and with participant safety as a priority.
